Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 8/20 | 0.42 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | HTR1F | P30939 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2315654 | 0.83 | NPY5R (0.61) | NPY5R | |
| SCHEMBL2317358 | 0.83 | NPY5R (0.49) | NPY5R | |
| SCHEMBL2317308 | 0.82 | DYRK1A (0.42) | PDCD1LG2CD274 | |
| SCHEMBL2359910 | 0.76 | MAP4K4 (0.40) | SCN9ATRPA1MAP4K4 | |
| SCHEMBL2322306 | 0.73 | GSK3B (0.42) | — | |
| SCHEMBL2318020 | 0.73 | TSHR (0.56) | — | |
| SCHEMBL2323355 | 0.69 | FFAR4 (0.46) | SCN9AFFAR4MAP4K4 | |
| SCHEMBL13362183 | 0.68 | NPY5R (0.60) | NPY5R | |
| SCHEMBL12284422 | 0.68 | NPY5R (0.60) | NPY5R | |
| SCHEMBL12283674 | 0.64 | NPY5R (0.49) | NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| EP-2352730-A2 | BIOLOGICALLY ACTIVE AMIDES | H. Lundbeck A/S (DK) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010053861-A2 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010053861-A2 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | NPY5R, NPY1R, NPY2R | NPY5R 1/4885PDCD1LG2 4056/4885CD274 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.